SEARCH:   Advanced

Blood, 15 July 2006, Vol. 108, No. 2, pp. 697-704. Prepublished online as a Blood First Edition Paper on April 4, 2006; DOI 10.1182/blood-2005-11-4687. This Article Full Text (PDF) All Versions of this Article: 2005-11-4687v1 108/2/697    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by White, D. L Articles by Hughes, T. P Search for Related Content PubMed PubMed Citation Articles by White, D. L Articles by Hughes, T. P Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 28, 2005 Accepted March 6, 2006 OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Deborah L White*, Verity A Saunders, Phuong Dang, Jane Engler, Andrew C Zannettino, Antony C Cambareri, Steven R Quinn, Paul W Manley, and Timothy P Hughes Division of Hematology, Institute of Medical and Veterinary Science and Hanson Institute, Adelaide, South Australia, Australia; The University of Adelaide, Adelaide, South Australia, Australia Division of Hematology, Institute of Medical and Veterinary Science and Hanson Institute, Adelaide, South Australia, Australia Novartis Pharmaceuticals, Sydney, New South Wales, Australia Novartis Institutes of Biomedical Research, Basel, Switzerland * Corresponding author; email: deb.white{at}imvs.sa.gov.au. Intrinsic sensitivity of , newly diagnosed CML patients to imatinib (IC50imatinib) correlates with molecular response. IC50imatinib is defined as the in-vitro concentration of drug required to reduce phosphorylation of the adaptor protein Crkl by 50%. We now show that interpatient variability in IC50imatinib is mainly due to differences in the efficiency of imatinib intracellular uptake and retention (IUR). In 25 untreated CML patients the IC50imatinib strongly correlated (R2 = -0.484, p = 0.014 at 2µM imatinib) with the IUR of [14C]imatinib. The addition of prazosin, a potent inhibitor of OCT-1 cellular transporter reduced the IUR, and eliminated interpatient variability. IC50 values for the more potent BCR-ABL inhibitor nilotinib (AMN107) did not correlate with IC50imatinib (R2 = -0.0561, p>0.05). There was also no correlation between IC50nilotinib and the IUR for [14C]nilotinib (R2 = 0.457, p>0.05). Prazosin had no effect on nilotinib IUR suggesting that influx of nilotinib is not mediated by OCT-1. In conclusion, whereas OCT-1 mediated influx may be a key determinant of molecular response to imatinib, it is unlikely to impact on cellular uptake and patient response to nilotinib. Determining interpatient and interdrug differences in cellular uptake and retention could allow individual optimization of kinase inhibitor therapy CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Milojkovic and J. Apperley Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2009; 15(24): 7519 - 7527. [Abstract] [Full Text] [PDF] G. Rosti, F. Palandri, F. Castagnetti, M. Breccia, L. Levato, G. Gugliotta, A. Capucci, M. Cedrone, C. Fava, T. Intermesoli, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia Blood, December 3, 2009; 114(24): 4933 - 4938. [Abstract] [Full Text] [PDF] S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M. A. Rudek, A. Sparreboom, and S. D. Baker Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters Clin. Cancer Res., October 1, 2009; 15(19): 6062 - 6069. [Abstract] [Full Text] [PDF] G. D. Demetri, P. G. Casali, J.-Y. Blay, M. von Mehren, J. A. Morgan, R. Bertulli, I. Ray-Coquard, P. Cassier, M. Davey, H. Borghaei, et al. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors Clin. Cancer Res., September 15, 2009; 15(18): 5910 - 5916. [Abstract] [Full Text] [PDF] W. W. Zhang, J. E. Cortes, H. Yao, L. Zhang, N. G. Reddy, E. Jabbour, H. M. Kantarjian, and D. Jones Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance J. Clin. Oncol., August 1, 2009; 27(22): 3642 - 3649. [Abstract] [Full Text] [PDF] D. H. Kim, L. Sriharsha, W. Xu, S. Kamel-Reid, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4750 - 4758. [Abstract] [Full Text] [PDF] D. J. Kominsky, J. Klawitter, J. L. Brown, L. G. Boros, J. V. Melo, S. G. Eckhardt, and N. J. Serkova Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells Clin. Cancer Res., May 15, 2009; 15(10): 3442 - 3450. [Abstract] [Full Text] [PDF] M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood, May 7, 2009; 113(19): 4497 - 4504. [Abstract] [Full Text] [PDF] D. Bixby and M. Talpaz Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance Hematology, January 1, 2009; 2009(1): 461 - 476. [Abstract] [Full Text] [PDF] D. White, P. Dang, K. G. Obbink, A. Frede, C. Kok, T. P Hughes, and R. D'Andrea Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 723 - 723. [Abstract] A. Giannoudis, A. Davies, C. M. Lucas, R. J. Harris, M. Pirmohamed, and R. E. Clark Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia Blood, October 15, 2008; 112(8): 3348 - 3354. [Abstract] [Full Text] [PDF] J. Wu, F. Meng, L.-Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, et al. Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase J Natl Cancer Inst, July 2, 2008; 100(13): 926 - 939. [Abstract] [Full Text] [PDF] D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications Clin. Cancer Res., June 15, 2008; 14(12): 3881 - 3888. [Abstract] [Full Text] [PDF] S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom Interaction of Imatinib with Human Organic Ion Carriers Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148. [Abstract] [Full Text] [PDF] S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120. [Abstract] [Full Text] [PDF] A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Blood, April 15, 2008; 111(8): 4355 - 4364. [Abstract] [Full Text] [PDF] J. W. Polli, J. E. Humphreys, K. A. Harmon, S. Castellino, M. J. O'Mara, K. L. Olson, L. St. John-Williams, K. M. Koch, and C. J. Serabjit-Singh The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions Drug Metab. Dispos., April 1, 2008; 36(4): 695 - 701. [Abstract] [Full Text] [PDF] J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, Z. Peng, M. Talpaz, and N. J. Donato Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood, April 1, 2008; 111(7): 3821 - 3829. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] G. Minuesa, S. Purcet, I. Erkizia, M. Molina-Arcas, M. Bofill, N. Izquierdo-Useros, F. J. Casado, B. Clotet, M. Pastor-Anglada, and J. Martinez-Picado Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 558 - 567. [Abstract] [Full Text] [PDF] D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, and T. Hughes Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood, December 1, 2007; 110(12): 4064 - 4072. [Abstract] [Full Text] [PDF] D. L. White, V. A. Saunders, S. R. Quinn, P. W. Manley, and T. P. Hughes Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs Blood, April 15, 2007; 109(8): 3609 - 3610. [Full Text] [PDF] E. Weisberg, L. Catley, R. D. Wright, D. Moreno, L. Banerji, A. Ray, P. W. Manley, J. Mestan, D. Fabbro, J. Jiang, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias Blood, March 1, 2007; 109(5): 2112 - 2120. [Abstract] [Full Text] [PDF] N. P. Shah Medical Management of CML Hematology, January 1, 2007; 2007(1): 371 - 375. [Abstract] [Full Text] [PDF] M. J. Mauro Defining and Managing Imatinib Resistance Hematology, January 1, 2006; 2006(1): 219 - 225. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020